AVKARE Inc. is recalling 274 cartons of Duloxetine Delayed-release Capsules USP, 20 mg (generic Cymbalta), a prescription medication used to treat depression and anxiety. This recall was initiated because testing found slightly elevated levels of phthalic acid, an impurity that failed to meet the required quality and degradation specifications. These products were distributed nationwide across the United States in unit-dose blister packs containing 50 capsules each.
The presence of elevated phthalic acid indicates the medication is degrading or contains impurities beyond safe pharmaceutical standards. This may reduce the effectiveness of the drug or expose patients to unintended chemical byproducts, though no specific injuries have been reported.
Contact healthcare provider and return product
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.